Interleukin-6 gene polymorphisms in Egyptian children with febrile seizures: a case-control study

Seham F Azab1, Mohamed A Abdalhady2, Alshaymaa Ali3

  • 1Faculty of Medicine, Zagazig University, 18 Omar Bin Elkhattab St, Al Qawmia, Zagazig City, AlSharqia Governorate, Egypt. Seham_Azab@yahoo.com.

Insights

Certain interleukin-6 (IL6) gene variations are linked to an increased risk of febrile seizures in Egyptian children. Specifically, the -174 GG genotype and the -597 GG genotype are identified as risk factors for febrile seizures.

Area of Science:

  • Genetics
  • Pediatrics
  • Immunology

Background:

  • Febrile seizures are the most common seizures in children.
  • Interleukin-6 (IL6) is a key pro-inflammatory cytokine.
  • Limited research exists on IL6 gene polymorphisms and febrile seizures.

Purpose of the Study:

  • Investigate the association between IL6 gene polymorphisms (-174, -572, -597) and febrile seizures in Egyptian children.
  • Determine if specific IL6 genotypes are risk factors for febrile seizures.
  • Examine the relationship between IL6 genotypes and serum IL6 levels.

Main Methods:

  • Case-control study with 100 febrile seizure patients and 100 healthy controls.
  • Genotyping of IL6 polymorphisms (-174 G/C, -572 G/C, -597 G/A) using PCR-RFLP.
  • Measurement of serum IL6 levels via ELISA.

Main Results:

  • Increased frequency of IL6 -174 GG and -597 GG genotypes in children with febrile seizures.
  • Significant association between IL6 -597 GG genotype and G allele with susceptibility to complex febrile seizures.
  • No association found between IL6 genotypes and serum IL6 levels.

Conclusions:

  • IL6 gene polymorphisms at -174 (G allele/GG genotype) and -597 (GG genotype) are risk factors for febrile seizures in Egyptian children.
  • The IL6 -597 GG genotype and G allele are associated with increased susceptibility to complex febrile seizures.
  • No correlation exists between IL6 genotypes and serum IL6 levels in febrile seizure patients.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.1K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
108
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66